File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1089/scd.2014.0203
- Scopus: eid_2-s2.0-84913615100
- PMID: 25050446
- WOS: WOS:000343602900002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics
Title | A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics |
---|---|
Authors | |
Issue Date | 2014 |
Citation | Stem Cells and Development, 2014, v. 23 n. 21, p. 2553-2567 How to Cite? |
Abstract | Intervertebral disc degeneration is associated with low back pain. Mesenchymal stem cells (MSCs) have been used to "regenerate" the disc. The aim of this study was to perform a systematic review of comparative controlled studies assessing the safety and efficacy of using MSCs in animal in disc regeneration. Literature databases were extensively searched. Trial design, MSC sources, injection method, disc assessment, outcome intervals, and complication events were assessed. Validity of each study was performed. Twenty-four animal studies were included with 20.8% of the studies reporting randomization of groups. The studies represented 862 discs that were injected with MSCs and 1,603 discs as controls. All three types of MSCs (i.e. bone marrow, synovial and adipose tissue) showed successful inhibition of disc degeneration. Bone marrow-derived MSCs demonstrated superior quality of repair compared with other non-MSC treatments. A 2.7% overall complication rate was noted, whereby complications were noted only in rabbits. Overall, evidence suggested that MSCs increased disc space height in the majority of animal models. This is the first systematic review to assess the safety and efficacy of MSC for the treatment of disc degeneration. Short-term MSC transplantation is safe and effective; however, additional, larger and higher-quality studies are needed to assess the long-term safety and efficacy. Inconsistency in methodological design and outcome parameters prevent any robust conclusions. Recommendations are further made to improve efficacy, reduce potential complications, and standardize techniques for future studies. |
Persistent Identifier | http://hdl.handle.net/10722/220166 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.803 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, RLH | - |
dc.contributor.author | Lee, TY | - |
dc.contributor.author | Bow, HYC | - |
dc.contributor.author | Meij, B | - |
dc.contributor.author | Leung, VYL | - |
dc.contributor.author | Cheung, KMC | - |
dc.contributor.author | Vavken, P | - |
dc.contributor.author | Samartzis, D | - |
dc.date.accessioned | 2015-10-16T06:31:18Z | - |
dc.date.available | 2015-10-16T06:31:18Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Stem Cells and Development, 2014, v. 23 n. 21, p. 2553-2567 | - |
dc.identifier.issn | 1547-3287 | - |
dc.identifier.uri | http://hdl.handle.net/10722/220166 | - |
dc.description.abstract | Intervertebral disc degeneration is associated with low back pain. Mesenchymal stem cells (MSCs) have been used to "regenerate" the disc. The aim of this study was to perform a systematic review of comparative controlled studies assessing the safety and efficacy of using MSCs in animal in disc regeneration. Literature databases were extensively searched. Trial design, MSC sources, injection method, disc assessment, outcome intervals, and complication events were assessed. Validity of each study was performed. Twenty-four animal studies were included with 20.8% of the studies reporting randomization of groups. The studies represented 862 discs that were injected with MSCs and 1,603 discs as controls. All three types of MSCs (i.e. bone marrow, synovial and adipose tissue) showed successful inhibition of disc degeneration. Bone marrow-derived MSCs demonstrated superior quality of repair compared with other non-MSC treatments. A 2.7% overall complication rate was noted, whereby complications were noted only in rabbits. Overall, evidence suggested that MSCs increased disc space height in the majority of animal models. This is the first systematic review to assess the safety and efficacy of MSC for the treatment of disc degeneration. Short-term MSC transplantation is safe and effective; however, additional, larger and higher-quality studies are needed to assess the long-term safety and efficacy. Inconsistency in methodological design and outcome parameters prevent any robust conclusions. Recommendations are further made to improve efficacy, reduce potential complications, and standardize techniques for future studies. | - |
dc.language | eng | - |
dc.relation.ispartof | Stem Cells and Development | - |
dc.title | A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics | - |
dc.type | Article | - |
dc.identifier.email | Bow, HYC: cbow@hku.hk | - |
dc.identifier.email | Leung, VYL: vicleung@hku.hk | - |
dc.identifier.email | Cheung, KMC: cheungmc@hku.hk | - |
dc.identifier.email | Samartzis, D: dspine@hku.hk | - |
dc.identifier.authority | Leung, VYL=rp01764 | - |
dc.identifier.authority | Cheung, KMC=rp00387 | - |
dc.identifier.authority | Samartzis, D=rp01430 | - |
dc.identifier.doi | 10.1089/scd.2014.0203 | - |
dc.identifier.pmid | 25050446 | - |
dc.identifier.pmcid | PMC4201280 | - |
dc.identifier.scopus | eid_2-s2.0-84913615100 | - |
dc.identifier.hkuros | 256007 | - |
dc.identifier.hkuros | 238014 | - |
dc.identifier.volume | 23 | - |
dc.identifier.spage | 2553 | - |
dc.identifier.epage | 2567 | - |
dc.identifier.isi | WOS:000343602900002 | - |
dc.identifier.issnl | 1547-3287 | - |